Ashima Lyall MBBS, Presenter: Nothing to Disclose

Masanori Ichise MD, Abstract Co-Author: Consultant, Navidea Biopharmaceuticals, Inc Research support, Piramal Enterprises Limited Research support, Bayer AG

1. Discuss the pathophysiology and classification of lymphoma. 2. Discuss the value of molecular imaging, in particular FDG PET imaging in the detection, staging, assessment of response to therapy and detection of recurrence of lymphoma. 3. Discuss the differences in metabolic activityand FDG avidity of various lymphoma types with pathological correlation. 4. Discuss mimickers of lymphoma.

I. Classification of lymphomas. II. Relative incidence of lymphoma subtypes. III. Staging of lymphomas. IV. PET biomarkers in lymphoma imaging. V. Mechanism of FDG uptake by the tumor cell. VI. FDG avidity in lymphoma subtypes. VII. Early prediction ofresponse to therapy of lyphomas with FDG PET. VIII. Mimickers of lymphoma. IX. Future directions in imaging of lymphoproliferative disorders.

http://abstract.rsna.org/uploads/2014/14014760/14014760_ssd6.pdf

Lyall, A, Ichise, M, Positron Emission Tomography (PET) Imaging of Lymphoproliferative Disorders: An Overview with Rad-path Correlation.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14014760.html